Browsing Tag
Anthony O. Caggiano
1 post
Why CGTX stock could draw attention after FDA alignment on DLB psychosis
Cognition Therapeutics’ FDA alignment gives zervimesine a clearer DLB psychosis path, sharpening CGTX’s dementia drug development and stock story.